Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor ... ( How did a failed contraceptive becom...)

Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators

Date:2/15/2008

How did a failed contraceptive become the first targeted therapy for the treatment of breast cancer" The transformation of tamoxifen, from cast-off to lifesaver, laid the foundation for a new class of therapeutics selective estrogen receptor modulators that could treat or prevent a variety of human diseases, including cancer and osteoporosis, according to V. Craig Jordan, OBE, Ph.D., D.Sc., a researcher at the Fox Chase Cancer Center in Philadelphia.

Today at the 2008 Annual Meeting of the American Association for the Advancement of Science, Jordan reports on efforts to use the lessons learned about tamoxifen to develop new hormone receptor-related drugs for both women and men. His presentation will be part of a symposium, held from 1:45 p.m. to 4:45 p.m., entitled Progress in Cancer Prevention.

As both a preventative and therapeutic agent, tamoxifen has been credited with saving the lives of more than a half million women over the last 30 years, says Jordan, the Alfred G. Knudson Jr., M.D., Ph.D., Chair in Cancer Research at Fox Chase. The process of discovery that made tamoxifen a reality has given us insights into molecular mechanisms that are currently being used to advance the creation and refinement of better drugs.

In the 1970s, Jordans laboratory pioneered the work that turned tamoxifen into a cancer therapy, which then jump-started a field of study into so-called designer estrogens. These drugs, called selective estrogen receptor modulators (SERMS), can have different effects on their targets, estrogen receptors, depending on where the receptor is located within a woman's body. The SERM raloxifene, for example, exhibits an anti-estrogen activity that can prevent cancer in breast tissue, but in other tissue the same drug has an estrogen-like effect that increases bone density. Currently, raloxifene, which was also developed in Jordans laboratory, is approved in post-menopausal women to prevent osteoporosis and treat brea
'/>"/>

Contact: Greg Lester
gregory.lester@fccc.edu
215-316-8977
Fox Chase Cancer Center
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Congressional Budget Includes Earmark to Keep Washingtons Sexual Assault DNA Program Moving Forward
2. AUDIO from Medialink and GlaxoSmithKline: Get Ready to Get Moving to a New You in the New Year
3. After Dropping 162 Pounds, Jodi Davis Inspires Other Michigan Women to Get Moving and Lose Weight Through WalkyTalk.com(TM)
4. Growth Needs Space: joimax, Inc. USA, is Moving Into New Premises
5. GPS-like technology helps pinpoint best methods for moving injured players
6. Removing Ovaries Before Menopause Leads to Memory, Movement Troubles
7. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
8. Michigan Kidney Patient Goes Above and Beyond to Help His Community - Awarded National DPC Hero Award
9. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
10. Ashley Forms Partnership With Roger Burgess and ProCare Rx to Carry Gotham Banner into 2008 and Beyond
11. 10 Cities to Participate in Live Well! Life Beyond Cancer Program Sponsored by The Wellness Community and the Lance Armstrong Foundation

Post Your Comments:

(Date:5/21/2013)... Parker Waichman LLP, a national law firm dedicated ... devices, is offering remarks on the closing argument of the ... E. Taylor v. Intuitive Surgical, 09-2-03136-5, Superior Court, State of ... Bloomberg report noted that the plaintiff’s attorney, after noting ... how it deployed its strategy to train doctors to use ...

(Date:5/21/2013)... Primary care practice transformation on a large scale ... efforts aimed at achieving better outcomes, better value ... that transformation toward the patient-centered medical home model ... environment, the U.S. Department of Health and Human ... 14 studies to learn more about the processes ...

(Date:5/21/2013)... drugs which lower intraocular pressure, are often the first ... use is not without risks. PGAs have long been ... and other side effects. Now a new study has ... eyelid drooping and other issues that can interfere with ... . , Researchers from the Massachusetts Eye and Ear ...

(Date:5/21/2013)... San Antonio, TX (PRWEB) May 21, 2013 ... report from the Texas Department of Aging and Disability ... home visits and employee interviews, ContinuCare Home Health ... , The review is part of the Department ... comprehensive array of aging and disability services, supports ...

(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...

Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2 Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5 Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6 Health News:Glaucoma drug can cause droopy eyelids 2 Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2 Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3

[0] Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership [0] AHRQ-funded journal supplement offers lessons on primary care practice transformation [0] Glaucoma drug can cause droopy eyelids [0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services [0] Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants

... Medicine at Harvard Medical School and Beth Israel Deaconess ... Lectureship at the annual meeting of the Federation of ... month in Washington, DC. Named in honor of ... for radioimmunoassay led to discoveries that have helped to ...

... By Maureen Salamon HealthDay Reporter , THURSDAY, ... N.C., was in her early forties when she developed anorexia ... "In the middle of a disorder like that, you ... you," she said. Luckily, Hodgin sought the care of ...

... people develop diabetes because they don,t have enough pancreatic beta ... sugar levels. But what if other cells ... cells? Could we potentially cure diabetes? Researchers ... an important step in that direction. They report in the ...

... PHILADELPHIA Black cardiac arrest victims are more likely ... a large black population than when they,re brought to hospitals ... research from the University of Pennsylvania School of Medicine. The ... American Heart Journal . The Penn team found that, ...

... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...

... Vision and Ophthalmology (ARVO) is pleased to announce its 2011 ... the ARVO 2011 Annual Meeting, May 1 5, in ... MD, PhD, FARVO, Mildred Weisenfeld Award for Excellence in Ophthalmology: ... James T. Rosenbaum, MD, FARVO, Cogan Award: Andrew J. Fischer, ...

Cached Medicine News:Health News:Christos Mantzoros honored by Federation of the American Societies for Experimental Biology 2 Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2 Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3 Health News:Researchers discover mechanism that could convert certain cells into insulin-making cells 2 Health News:Black cardiac arrest patients more likely to be admitted to hospitals with lowest survival rates 2 Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2 Health News:2011 ARVO Award recipients honored at annual meeting 2 Health News:2011 ARVO Award recipients honored at annual meeting 3

Christos Mantzoros honored by Federation of the American Societies for Experimental Biology Bringing Partner Into Anorexia Treatment May Aid Recovery Researchers discover mechanism that could convert certain cells into insulin-making cells Black cardiac arrest patients more likely to be admitted to hospitals with lowest survival rates Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2011 ARVO Award recipients honored at annual meeting

(Date:5/21/2013)... May 21, 2013 Reaching a critical milestone ... National Association of Boards of Pharmacy ® (NABP ... domain suffix has passed the Internet Corporation for Assigned ... launch the .PHARMACY gTLD by the end of 2013, ... online pharmacies and related entities that are located in ...

(Date:5/21/2013)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China and the parent of Chang,an Hospital, today reported ... ended March 31, 2013 [1] . First ... consists of net revenues generated from the network business ...

(Date:5/21/2013)... LAWRENCE, Mass. , May 21, 2013 NxStage ... manufacturer of innovative dialysis products, today announced that it ... home, critical care and in-center products to DaVita, the ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) For the ... the United States , NxStage has executed a ...

[0] NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation [0] Concord Medical Reports First Quarter 2013 Financial Results [0] NxStage Announces New Agreements with DaVita

... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announced ... from a randomized Phase 2 clinical trial of,OGX-011 ... arm"),compared to docetaxel and prednisone alone ("the control ... cancer. The current 10.6,month median overall survival ...

... DIEGO, Dec. 3 Vical Incorporated,(Nasdaq: VICL ... with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and ... and the Turkish,Republic of Northern Cyprus. EIP has agreed ... to pay Vical upfront and milestone payments,plus a specified ...

Cached Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2 Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3 Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4 Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2 Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3 Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4 Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5

Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey

... EBI OsteoGen surgically implanted bone growth stimulator is ... when surgery is already planned or when patient ... is totally surgically implanted, patients are assured of ... hours a day for up to 6 months. ...

Our products, with carefully researched design features, are tailored to making arthroscopic and ligament reconstructive surgery more reproducible, easier, quicker and safer....

... Interference Screw has unique, double-helix ... while limiting veering and divergence. ... abrasion where it is most ... thread enables screws to be ...

... SmartScrew ACL Interference Screw is indicated ... including ACL and PCL reconstructions with ... and allografts. The SmartScrew ACL provides ... graft retention for any graft type. ...

Medicine Products:

EBI OsteoGen Implantable Bone Growth Stimulator Interference Screws Propel Cannulated Interference Screw SmartScrew ACL